Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Sinovac Biotech Ltd.    SVA   AGP8696W1045

SINOVAC BIOTECH LTD.

(SVA)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

China's Sinovac vaccine to be included in Brazil's immunization program, governors say

10/20/2020 | 04:04pm EST

BRASILIA, Oct 20 (Reuters) - The Brazilian government will include China's Sinovac vaccine against COVID-19 in its national immunization program, state governors said on Tuesday after a meeting with the country's health minister, in addition to one developed by AstraZeneca and Oxford University.

This means the experimental Chinese vaccine called Coronavac, which Brazil's largest state of Sao Paulo had hoped to provide to its residents, may also be used to vaccinate Brazilians elsewhere, a major success for Sinovac in a nation of 230 million people.

The federal government already has plans to purchase the UK vaccine and produce it at its biomedical research center FioCruz in Rio de Janeiro, while the Chinese vaccine is being tested by Sao Paulo state's research center Butantan Institute.

Sao Paulo governor Joao Doria said after the Health Ministry meeting that the federal government has agreed to buy 46 million doses of the Sinovac vaccine.

The national vaccination program could begin in January 2021, he said, which could make it one of the first immunization efforts against coronavirus in the world.

The Butantan Institute said on Monday that preliminary results from late-stage clinical trials of CoronaVac on 9,000 volunteers have proven that the two-dose Chinese vaccine is safe.

Butantan director Dimas Covas said data on how effective the vaccine is will not be released until the trial is completed.

The result is only preliminary and researchers will keep monitoring the participants in the ongoing trial, Covas said. It's the first set of results of Sinovac's global Phase 3 trials, which are also being conducted in Turkey and Indonesia.

The Sao Paulo government has already asked health regulators to approve CoronaVac for use, a major step in what could be one of the first vaccination programs in the Americas.

(Reporting by Anthony Boadle; Editing by Christian Plumb)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.67% 7748 Delayed Quote.1.85%
DIAGNOSTICOS DA AMÉRICA S.A. 0.50% 60 End-of-day quote.3.97%
MODERNA, INC. 10.78% 109.18 Delayed Quote.458.18%
SINOPHARM GROUP CO., LTD. 0.00% 19.74 End-of-day quote.-30.62%
SINOVAC BIOTECH LTD. -0.31% 6.47 Delayed Quote.-6.77%
US DOLLAR / TURKISH LIRA (USD/TRY) -0.06% 7.8658 Delayed Quote.32.38%
All news about SINOVAC BIOTECH LTD.
11/23Brazil has enough infection data to analyze Sinovac's COVID-19 vaccine - offi..
RE
11/23Sao Paulo expects regulator approval for Sinovac vaccine by January
RE
11/23Q&A : Where are we in the COVID-19 vaccine race?
RE
11/20SINOVAC BIOTECH : Pfizer eyes rapid COVID-19 vaccine roll-out in Latam after U.S..
RE
11/20Britain asks regulator to assess Pfizer vaccine for suitability
RE
11/20UK asks regulator to assess Pfizer vaccine for suitability
RE
11/20Sinovac may get Phase III trial results of COVID-19 vaccine by December, exec..
RE
11/17Brazil to receive China's Sinovac COVID-19 vaccine, eyes Pfizer candidate
RE
11/17Sinovac's COVID-19 vaccine induces quick immune response - study
RE
11/17Sinovac's COVID-19 vaccine induces quick immune response - study
RE
More news
Financials (USD)
Sales 2019 246 M - -
Net income 2019 44,9 M - -
Net cash 2019 183 M - -
P/E ratio 2019 17,8x
Yield 2019 -
Capitalization 640 M 640 M -
EV / Sales 2018 1,38x
EV / Sales 2019 1,86x
Nbr of Employees 910
Free-Float 50,1%
Chart SINOVAC BIOTECH LTD.
Duration : Period :
Sinovac Biotech Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Wei Dong Yin Chairman, President, CEO, Secretary & MD
Nan Wang Chief Financial Officer & Vice President
Qiang Gao Vice President-Research & Development
Yuk Lam Lo Independent Director
Jian Li Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
SINOVAC BIOTECH LTD.-6.77%640
CSL LIMITED11.34%103 950
SAMSUNG BIOLOGICS CO.,LTD.84.53%48 002
BIOGEN INC.-18.53%37 201
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO.,LTD.138.48%29 065
ALEXION PHARMACEUTICALS, INC.13.83%26 903